Immunological and Viral Response to Antiretrovirals in HIV Patients With CD4 Cell Count Below 100
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The study analyzes the virological response in plasma and non-plasma compartments, as well as the degree and kinetics of immune reconstitution in 70 treatment-naive patients with CD4 < 100/mm3, when they receive treatment with two nucleoside analogs (NRTI) plus one protease inhibitor (PI) compared with 2 NRTI plus one non-nucleoside (NNRTI).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosed HIV-1 infection.
Age 18 years or over.
No previous antiretroviral therapy.
CD4 lymphocyte count of < 100 cells/mL.
Patients who, sufficiently informed, give their written consent to participate in the study and undergo the tests and explorations involved in the study.
Pregnant women, women who are breast feeding, or women who intend to become pregnant during the study period.
Currently undergoing treatment for an opportunistic infection (parenteral administration).
Any formal contraindication to treatment with the study drugs